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Abstract 
Background: Accumulating evidence has shown that valproate has the greatest 
teratogenic potential, increasing the risk of major congenital malformations, such as 
neural tube defects, cleft palate, and neurodevelopmental disability. Some global 
guidelines state that valproate should not be used for girls or women of childbearing age 
with bipolar disorder, although valproate is a pharmacological option for acute mania and 
is used as a stabilization drug for patients with bipolar disorder. We investigated patterns 
in psychiatrists’ prescription of valproate for female patients of childbearing age with 
bipolar disorder in Japan. 
Methods: We conducted a questionnaire survey about psychiatric practice as it relates to 
major depression and bipolar disorder throughout women's life cycles with respect to 
psychiatrists from all prefectures in Japan from March to May 2018. The questionnaire 
had two parts: (1) assessment of participating psychiatrists’ backgrounds and attitudes 
toward patients and (2) their patterns of prescription of psychotropics for female patients 
with mood disorders across generations and periods of pregnancy. Each question item 
had four response options: “not at all,” “rarely,” “sometimes,” and “frequently.” We 
examined patterns of prescription for childbearing-age women (late adolescence/young 
adulthood aged 18-24 years, childbearing-age, older adults aged 25-49 years) and during 
pregnancy periods.  
Results: In total, 571 psychiatrists (427 males, 123 females, and 21 unknowns) responded 
appropriately to the questionnaire, including 320 who examined at least one or more late 
adolescence/young adulthood bipolar women. Approximately 70% of psychiatrists 
answered that they frequently or sometimes prescribe valproate for bipolar women of 
childbearing age [late adolescence/young adulthood: not at all, n = 23 (7.5%); rarely, n = 
69 (22.5%); sometimes, n =116 (37.8%); and frequently, n = 99 (32.2%); childbearing-
age, older adults: not at all, n = 13 (2.7%); rarely, n = 67 (13.8%); sometimes, n = 185 
(38.1%); and frequently, n = 220 (45.4%)]. The proportion of general hospital 
psychiatrists who answered “not at all” or “rarely” to the frequency of their valproate 
prescriptions was higher than that of psychiatrists working in other medical facilities 
(χ2(3) = 18.2, p < 0.001). 
Conclusion: Most psychiatrists frequently or sometimes prescribe valproate for women 
of childbearing age in Japan.  
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1. Introduction 
Bipolar disorder frequently emerges in late teenagers and young adults (1-3) and its 
prevalence in males and females is the same (4). The nature, course and prognosis of 
bipolar disorder include a tendency towards remission and recurrent mood episodes (5), 
frequent comorbidities such as substance use and anxiety disorders (6), decreased quality 
of life and neurocognitive functioning in various domains such as work and family life 
(7, 8), and high mortality characterized by not only suicide (9, 10), but also general 
medical conditions (11). Therefore, the burden of this illness is serious in young bipolar 
patients that need continuous, ongoing management.  
Pharmacological treatment plays a crucial role in the continuous management of 
patients with bipolar disorder in the form of therapies for any mood episodes, including 
mania and depression, and as continued treatment for the prevention of any episodes in 
the maintenance phase, according to several worldwide guidelines (12-14). However, in 
the case of girls, women of childbearing age and pregnant women with bipolar disorder, 
continuous medication is frequently difficult to successfully administer and the 
pharmacological strategy for these patients must be different from that for other patients, 
because newborns and children face risks of congenital malformations. Several guidelines 
for the management of bipolar disorder such as the National Institute for Health and Care 
Excellence: bipolar disorder: assessment and management [CG185] (NICE), last updated 
April 2018 (NICE 185 guideline) (15), the International College of Neuro-
Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-
BD-2017) (12), and the Canadian Network for Mood and Anxiety Treatments 
(CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for 
management of bipolar disorder (CANMAT-Bipolar Guidelines-2018) (14), commonly 
state that valproate should not be used for women of childbearing age due to its 
teratogenic potential. 
Although valproate is one of the pharmacological options for the treatment of acute 
mania and the maintenance of stabilization in patients with bipolar disorder, accumulating 
evidence has shown that valproate, among pharmacological treatments for bipolar 
disorder, has the greatest teratogenic potential as it increases the risk of major congenital 
malformations, such as neural tube defects, cleft palate (16, 17) and neurodevelopmental 
disability (18, 19). The CINP-BD-2017 states that valproate is not suitable for women of 
childbearing age. Moreover, the NICE 185 guideline and the UK National Institute for 
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Health and Care Excellence Clinical Guideline 192: antenatal and postnatal mental health 
clinical management and service guidance, last updated April 2018 (NICE 192 guideline) 
(20), state that valproate treatment must not be used for women, including young girls 
prior to puberty, unless alternative medications are not suitable or women are in a 
pregnancy prevention program. 
Our recent study that investigated the top 11 best-selling anticonvulsants and 
lithium using the National Insurance claims database in Japan, showed that valproate was 
the most prescribed major anticonvulsant for female outpatients of childbearing age, and 
was prescribed only slightly less than these, compared to the same-aged men using the 
National Insurance claims database from April 2014 to March 2015. However, the data 
preceded the publication of the above-mentioned guidelines (21). The results of our study 
stir concern with regard to whether most psychiatrists or physicians in Japan properly 
prescribe valproate for childbearing-aged women, who must be cautioned with regard to 
its high teratogenic potential, and given adequate instruction with regard to their methods 
of contraception during treatment. Based on the findings of our previous study, we 
hypothesized that most psychiatrists and physicians do not pay close attention to the 
possibility of pregnancy, or the method of contraception, when they prescribe valproate 
for childbearing-aged women, and that psychiatrists who pay attention to patients’ 
reproductive potential in their clinical practice only very cautiously consider prescribing 
valproate to bipolar women of childbearing age.  
The aim of the present study was to identify psychiatrists’ patterns of prescribing 
valproate for female patients with bipolar disorder of childbearing age (in their late 
adolescent years and late forties), compared to those who are pregnant, in Japan. 
Moreover, we also investigated the relationship between characteristics and reproduction-
related interviews in the consultation of psychiatrists and their frequency of valproate 
prescription. To assess this, this study was performed with the data from a questionnaire 
survey that we conducted about psychiatric practice in major depression and bipolar 
disorder throughout the woman’s life cycle by psychiatrists in all prefectures in Japan 
from March to May 2018. This study also examined the frequency of prescription of other 
mood stabilizers (lithium, carbamazepine, and lamotrigine), antipsychotics, and 
antidepressants in bipolar women of childbearing age and in the pregnancy period to 
compare them with prescriptions for valproate. 
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2. Materials and methods 
Study design and participants 
A cross-sectional study was conducted with psychiatrists who belong to the following 
associations: Association of Japan Psychiatric Clinics: Tokyo branch and Chiba branch, 
Association of Japan Psychiatric Hospitals: Ibaraki branch, Chiba branch and Tokyo 
branch, JSGHP; Japanese Society of General Hospital Psychiatry in 2018. 
A total of 1414 medical institutions (963 General hospitals, 343 mental clinics, and 108 
psychiatric hospitals) were chosen from the list of cooperation association and 4816 
questionnaires were mailed through the postal service between March and May 2018. 
There were 571 respondents (427 male, 123 female, and 21 unknowns; mean age = 45.9 
years, SD = 10.8). Psychiatrists who did not see patients of childbearing age (18 to 49 
years) were excluded. Of 571 respondents, 320 (56.0%) psychiatrists met the eligible 
criteria for evaluating the prescribing action of female bipolar patients in late 
adolescence/young adulthood, ages 18–24 years. Of 571 respondents, 497 (87.0%) 
psychiatrists met the eligible criteria for evaluating the prescribing action of female 
bipolar patients in early or middle age. Of 571 respondents, 571 (100.0%) psychiatrists 
met the eligible criteria for evaluating the prescribing action of female bipolar patients 
who were pregnant. 
At the beginning of the questionnaire, we declare the objectives of the study and our 
commitment to the confidentiality of respondents. Therefore, completing and mailing 
back the questionnaire was considered to reflect informed consent regarding 
participation in this study. The study’s protocol was approved by the ethics committees 
of the Graduate School of Medicine and School of Medicine, Chiba University (20 
November 2017). 
 
Measures 
Sociodemographic characteristics and prescription patterns of participants 
The questionnaire was used to assess participating psychiatrists’ backgrounds, attitudes 
towards patients, and prescribing behavior. With regard to psychiatrists’ backgrounds, 
participants were asked about their demographic data, including sex, age, years of 
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clinical experience, hospital facility, and the number of patients with depression and 
bipolar disorder they treat per month. With regard to attitudes toward patients, the 
psychiatrists rated how often they focus on problems specific to life stages when 
counseling their patients. The question was followed by four response options: “not at 
all,” “rarely,” “sometimes,” and “frequently.” In the present study, we focused 
measurements of psychiatrists’ attitudes toward patients’ fertility by asking how often 
psychiatrists inquire about the following: any menstrual disorder, whether patients want 
to bear children, methods of contraception, and feelings of rejection for medication 
during pregnancy and breast-feeding periods. In their prescribing behavior, psychiatrists 
were requested to indicate how often they prescribe 16 types of medicine, depending on 
patients’ life stages. The life cycle was divided into 7 stages: ages 0–11 corresponding 
to childhood, ages 12–17 corresponding to pubescence, ages 18–24 corresponding to 
late adolescence/young adulthood, ages 25–49 corresponding to early middle age, ages 
50–59 corresponding to late middle age, ages 65 and over 65 corresponding to senium, 
and the pregnancy period. We focused on childbearing age and the pregnancy period in 
this study. We defined childbearing age as being from 18 to 49 years and considered it 
to correspond to late adolescence and early middle age stages in this study. 
The 16 types of drugs were of four types: antidepressants, mood stabilizers, 
antipsychotics, and Kampo. A full list of the medications is as follows: Antidepressants: 
SSRI (Selective Serotonin Reuptake Inhibitors), SNRI (Serotonin and Norepinephrine 
Reuptake Inhibitors), Mirtazapine, Tricyclic antidepressants, Tetracyclic 
antidepressants. Mood stabilizer: Lithium carbonate, Sodium Valproate, Carbamazepine 
and Lamotrigine. Antipsychotics: Typical antipsychotic, Atypical antipsychotic; 
Risperidone, Olanzapine, Quetiapine, Aripiprazole and others atypical antipsychotics. 
Kampo (herbal medicine). 
 
Statistical analysis 
We first performed a Chi-squared test (χ2-test) for categorized variables to analyze 
categorical data between the current and previous affiliations of psychiatrists (i.e. 
general hospitals or other medical facilities) and the frequency of prescription of 
valproate for female bipolar patients among late adolescence/young adulthood. In 
addition, we calculated the partial correlations, controlling for sex, between years of 
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clinical experience, valproate prescription, and psychiatrists’ attitude toward bipolar 
patients of childbearing age and during pregnancy. For all tests, a two-tailed p < 0.05 
was considered statistically significant. All analyses were conducted using SPSS 22 
(Arbuckle, 2013). 
 
3. Results 
Psychiatrists’ trends for prescribing psychotropic drugs for female bipolar patients 
of childbearing age 
A total of 320 psychiatrists participated in the assessment of prescription trends for 
female, late adolescent/young adulthood patients with bipolar disorder. A total of 497 
psychiatrists participated in the assessment of prescription trends for bipolar female, 
early middle age patients. A total of 571 psychiatrists participated in the assessment of 
the prescription trends for pregnant patients. The participants demographic 
characteristics are shown in Table 1. 
In general, the psychotropic drug we chose was prescribed more for female bipolar 
patients of childbearing age than for pregnant patients. Among female patients of 
childbearing age, early middle age patients got more psychotropic drug prescriptions 
than late adolescence/young adulthood patients, as shown in Table 2. Among female 
patients of childbearing age, early middle age patients got more psychotropic drug 
prescriptions than did late adolescent/young adulthood patients. Psychiatrists prescribed 
valproate for female late adolescence/young adulthood patients with bipolar disorder; 23 
psychiatrists responded not at all, n = 23 (7.5%); rarely, n = 69 (22.5%); sometimes, n 
=116 (37.8%); and frequently, n = 99 (32.2%). Psychiatrists prescribed valproate for 
childbearing-age, older female patients with bipolar disorder; 13 psychiatrists responded 
not at all, n = 13 (2.7%); rarely, n = 67 (13.8%); sometimes, n = 185 (38.1%); and 
frequently, n = 220 (45.4%). While they avoided prescribing of VPA for pregnant 
patients, 387 psychiatrists responded “not at all” (75.3%) while 126 responded “rarely”–
“frequently” (24.7%). 
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Table 1. Social and demographic characteristics of participants (N = 571) 

 
 
n (%)
Male 427 (74.8)
Female 123 (21.5)
Unknown 21 (3.7)
Age (years)
Mean 45.9
Standard deviation 10.8
Years of clinical experience
<11 years 181 (33.1)
11 years to under 21 180 (32.9)
21years to under 31years 111 (20.3)
More than 30 years 61 (13.7)
Unknown 24 (4.2)
Facilities
general hospital 307 (53.8)
psychiatric hospital 151 (26.4)
clinic 62 (10.9)
others 7 (1.2)
Unknown 21 (3.7)
Specialized clinical department
Psychiatry (general) 537 (94.0)
Psychosomatic medicine 27 (4.7)
Child psychiatry 33 (5.8)
Others 7 (1.2)
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Table 2. Row point questionnaire answers regarding prescriptions for female bipolar patients  
 

Mood stabilizers
Valproate 23 (7.5) 69 (22.5) 116 (37.8) 99 (32.2) 13 (2.7) 67 (13.8) 185 (38.1) 220 (45.4) 387 (75.3) 79 (15.4) 31 (6.0) 16 (3.1)
Lithium carbonate 15 (5.8) 54 (17.5) 125 (40.6) 111 (36.2) 7 (1.4) 42 (8.7) 181 (37.3) 255 (52.6) 382 (74.0) 77 (14.9) 37 (7.2) 20 (3.9)
Carbamazepine 109 (35.9) 102 (33.6) 74 (24.3) 19 (6.3) 122 (25.5) 157 (32.8) 148 (30.9) 52 (11.9) 402 (77.9) 78 (15.2) 30 (5.8) 3 (0.6)
Lamotrigine 32 (10.5) 57 (18.7) 126 (41.3) 90 (29.5) 40 (8.4) 75 (15.7) 209 (43.6) 155 (32.4) 221 (42.9) 119 (23.1) 124 (24.1) 51 (9.9)
Antidepressants
SSRIs a 136 (44.2) 115 (37.3) 43 (14.0) 14 (4.5) 137 (28.2) 186 (38.3) 124 (25.5) 39 (8.0) 288 (55.7) 167 (32.3) 50 (9.7) 10 (1.9)
SNRIs b 108 (35.2) 120 (39.1) 63 (20.5) 16 (5.2) 184 (37.9) 173 (35.6) 96 (19.8) 32 (6.6) 323 (62.5) 152 (29.4) 34 (6.6) 8 (1.5)
Mirtazapine 122 (39.7) 117 (38.1) 55 (17.9) 13 (4.2) 168 (34.8) 167 (34.6) 121 (25.1) 27 (5.6) 324 (62.8) 146 (28.3) 39 (7.6) 7 (1.4)
Tricyclic antidepressants 233 (76.4) 61 (20.0) 10 (3.3) 1 (0.3) 341 (70.6) 106 (21.9) 33 (6.8) 3 (0.6) 455 (88.5) 53 (10.3) 5 (1.0) 1 (0.2)
Tetracyclic antidepressants 216 (70.4) 65 (21.2) 24 (7.8) 2 (0.6) 309 (63.8) 118 (24.4) 51 (10.5) 6 (1.2) 423 (82.1) 74 (14.4) 17 (3.3) 1 (0.1)
Antipsychotics
Risperidone 54 (17.7) 102 (33.4) 121 (39.7) 28 (9.2) 64 (13.3) 150 (31.2) 208 (43.2) 59 (12.3) 200 (38.8) 190 (36.8) 106 (20.5) 20 (3.9)
Olanzapien 20 (6.5) 79 (25.7) 144 (46.9) 64 (20.8) 20 (4.2) 93 (19.3) 242 (50.3) 126 (26.2) 161 (31.0) 180 (34.7) 144 (27.7) 33 (6.4)
Quetiapine 17 (5.5) 71 (23.1) 147 (47.9) 71 (23.1) 20 (4.1) 73 (15.1) 250 (51.9) 139 (28.8) 144 (27.7) 165 (31.8) 160 (30.8) 50 (9.6)
Aripiprazole 10 (3.3) 47 (15.6) 164 (53.6) 85 (27.8) 11 (2.3) 54 (11.2) 264 (54.8) 153 (31.7) 110 (21.3) 177 (34.3) 180 (34.9) 49 (9.5)
Other atypical antipsychotics 109 (36.2) 109 (36.2) 66 (21.9) 17 (5.6) 170 (36.1) 150 (31.8) 120 (25.5) 31 (6.6) 286 (56.5) 148 (29.2) 65 (12.8) 7 (1.4)
Typical antipsychotics C 171 (57.2) 69 (23.1) 42 (14.0) 17 (5.7) 229 (48.8) 124 (26.4) 85 (18.1) 31 (6.6) 342 (67.2) 114 (22.4) 43 (8.4) 9 (1.8)
Kampo medicine (Harbal medicine) 99 (32.7) 98 (32.3) 79 (26.1) 27 (8.9) 156 (33.0) 134 (28.3) 144 (30.4) 39 (7.8) 211 (41.1) 152 (29.6) 111 (21.6) 39 (7.6)
a SSRI: selective serotonin reuptake inhibitors (e.g., Paroxetine hydrochloride hydrate, Sertraline hydrochloride, Escitalopram oxalate, and Fluvoxamine maleate)
b SNRI: serotonin noradrenalin reuptake inhibitors (e.g., Duloxetine hydrochloride, Milnacipran hydrochloride, and Venlafaxine hydrochloride)
c Typical antipsychotics: eg., Chlorpromazine hydrochloride, Haloperidol, Levomepromazine maleate, Sultopride hydrochloride, Timiperone, and Zotepine
Childbearing age
Pregnant women (N  = 571) 
Late adolescence/Young adulthood (18-24 years;  N  = 320) Childbearing-age, older adults (25-49 years; N  = 497) 
Not at all Rarely Sometimes Frequently Not at all Rarely
n  (%) n  (%) n  (%)
Sometimes Frequently Not at all Rarely Sometimes Frequently
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Affiliation of psychiatrists and prescription of valproate for female bipolar patients 
among late adolescence/young adulthood 
The χ2-test showed that there were significant differences in the current affiliation of 
psychiatrists and valproate prescriptions for female bipolar patients among late 
adolescence/young adulthood, as shown in Table 3 (χ2(3) = 18.2, p < 0.001). A 
Haberman-type residual analysis showed that the number of psychiatrists working for 
general hospitals who reported that they prescribed valproate either “Not at all” or 
“Rarely” was higher than that of psychiatrists working for other medical facilities and 
hospitals. In addition, the number of psychiatrists working for general hospitals 
answered “Frequently” with regard to valproate prescription much less than 
psychiatrists working for other medical facilities or hospitals. In their previous 
affiliations, however, there were no differences between general hospitals and other 
medical facilities in terms of valproate prescriptions. 
 
Partial correlation between valproate prescribing action and psychiatrists’ 
backgrounds 
We calculated the partial correlations, controlling for sex, between years of clinical 
experience, valproate prescription, and psychiatrists’ attitude toward bipolar patients of 
childbearing age and in pregnancy (Table 4). The psychiatrists’ years of experience was 
found to be positively and significantly correlated with a valproate prescription in late 
adolescence/young adulthood (18-24 years) (r = 0.13, p < 0.05). In childbearing-age, 
older adults (25-49 years) and pregnant women, on the other hand, there is no 
relationship between the two variables. There is no relationship between the contents of 
reproductive-related medical interviews and valproate prescriptions in childbearing age 
or pregnancy. 
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Table 3. Affiliation of psychiatrist and valproate prescription for female bipolar patients among late adolescence/young 
adulthood (18-24 years of age) 

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Current Affiliation 18.2 0.001
General Hospitals 20 (11.3) 49 (27.7) 57 (32.2) 51 (28.8)
Other medical facilities 6 (4.2) 19 (13.2) 61 (42.4) 58 (40.3)
Previous Affiliation 5.3 0.2
General Hospitals 24 (8.1) 67 (22.7) 106 (35.9) 98 (33.2)
Other medical facilities 2 (7.7) 1 (3.8) 12 (46.2) 11 (42.3)
Note . p  value was calculated by the χ 2-test.
Prescription of Valproate
χ 2 p
n  (%)
FrequentlySometimesRarelyNot at all
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Table 4. Partial Correlation between valproate prescription and psychiatrists’ attitude toward bipolar patients of 
childbearing age and during pregnancy 
 
 
Years of clinical experience .13 * -.01 .01
Reproductive-related medical interview
Abnormal menstruation -.02 -.03 -.04
Having desire to bear children -.03 .03 -.04
Method of contraception .02 .01 .08
Internal medicine avoiding during
pregnancy and breast feeding .09 .06 -.05
Note . Partial Correlation coefficients were controlled for sex. *p  < .05.
Prescription of Valproate
Younger adults (18-
24 years)
Elder childbearing-
age adults (25-49
years)
Pregnant women
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4. Discussion 
In this study, three important findings about psychiatrists’ prescription patterns of 
valproate for female bipolar patients of childbearing age in Japan deserve to be mentioned. 
First, the present study demonstrates that 70% of psychiatrists responding to the 
questionnaire sheet answered that they frequently or occasionally tended to prescribe 
valproate for women of childbearing age in Japan, although most answered that they did 
not for women who were pregnant. Specifically, 32% of psychiatrists answered that they 
frequently prescribed valproate for women aged 18 to 24 years, and 38% of those 
occasionally prescribed it for same-aged women. Thirty percent of psychiatrists answered 
they rarely tended to prescribe valproate, or that they did not at all prescribe it. Second, 
psychiatrists affiliated with general hospitals answered that they tended to refrain from 
prescribing valproate for childbearing-age women compared to those affiliated with other 
medical facilities such as psychiatric hospitals or private clinics. Third, the frequencies of 
reproductive-related medical interviews were not correlated with the tendency to 
prescribe valproate to women of childbearing age, although years of psychiatric 
experience was positively correlated with this.  
This questionnaire study conducted from March to May 2018 reveals the possibility that 
more than half of psychiatrists frequently or occasionally tend to prescribe valproate for 
women of childbearing age in Japan. This finding is consistent with our previous study 
investigating prescribed tablets for childbearing-aged outpatients in Japan (21). On April 
6, 2017, in reference to pharmacological treatments of women in perinatal periods, the 
Japanese Society of Perinatal Mental Health published the Perinatal Mental Health 
Consensus Guide 2017 on the website (TCC?1		?YTSaUPQ;UZQO[Y	1 in Japanese only) that 
states that valproate should not be prescribed to women of childbearing age. However, 
the society has been as small as the number of psychiatrists, and there were only 20 
regular members at that time, while midwives constitute a large proportion of the regular 
members of the society (over 100 people). In other countries, such as Finland (22), Ireland 
(23), and Germany (24), valproate prescription has tended to slightly decline, although 
the data from these studies are not limited to pharmacological treatments of bipolar 
disorder. In the UK, at the same time as the last updated NICE 192 guideline, in April 
2018, the Medicines and Healthcare Products Regulatory Agency (MHRA) stated that 
valproate use would be rigidly regulated and that valproate treatment must not be used 
for women, including young girls prior to puberty, unless alternative medications are not 
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suitable and unless women are part of a pregnancy prevention program (25). Considering 
that fetal exposure to valproate in the first trimester must be avoided, and that 
approximately 40% of pregnancies are unplanned or unintended (26), psychiatrists and 
physicians should not prescribe valproate for girls and childbearing-age women with 
bipolar disorder, in principle. Furthermore, the societies, associations, and related 
guidelines that directly influence psychiatrists or physicians are expected to clearly share 
warnings with regard to valproate prescriptions for girls and childbearing-age women 
with bipolar disorder in Japan and other countries, because changes in valproate 
prescription patterns among these countries may be slow. 
In the present study, psychiatrists working at general hospitals answered that they 
tended to refrain from prescribing valproate to childbearing-age women compared to 
those affiliated with other medical facilities, such as psychiatric hospitals and private 
clinics. There are two main possible interpretations of this result. Freudenreich and 
Kontos report that consultation-liaison psychiatrists have better opportunities and 
situations for learning other medical specialties through their interdisciplinary 
collaborative work (27). This may make sense considering that psychiatrists working at 
general hospitals, compared to other institutions, have better chances and experience with 
regard to consulting pregnant women with psychiatric diseases at their hospitals which 
either have a birth center or obstetricians working in them. There are other reasons, too, 
for which psychiatric diseases and symptomatic and social severities of patients are 
different across general hospitals and other institutes. For instance, in/outpatients 
consulting psychiatrists in psychiatric hospitals may have more severe symptomatology, 
impaired social ability such as due to long-term hospitalization, and compromised 
cognitive performance, including in the form of intellectual disability, than those of 
general hospitals. Therefore, it is so difficult for such patients to become pregnant that 
psychiatrists prescribe valproate to them. However, in the real-world, women with severe 
mental illness such as schizophrenia and autism are fertile and do get pregnant and have 
newborns (28). Therefore, the societies and associations that largely influence any 
psychiatrists, regardless of any kinds of medical institutes, should provide warnings with 
regard to valproate prescription for girls and women of childbearing age. 
In addition, the frequencies of reproductive-related medical interviews were not 
correlated with the tendency to prescribe valproate to women of childbearing age, 
although years of psychiatric experience was positively correlated with this. These results 
(-

were unexpected because our hypothesis was that psychiatrists who usually pay attention 
to future conceptions in their consultations of childbearing-age women would not, in 
general, have prescribed valproate to these women. The interpretation of this result was 
that there may be two groups of psychiatrists with regard to pregnancy, consisting of the 
ones refraining from prescribing valproate to childbearing-age women, and the other ones 
prescribing it with caution. It is difficult to interpret the positive correlation between years 
of psychiatric experience and the tendency to prescribe valproate to childbearing-age 
women. This result is limited because of the lack of surveillance with regard to real-world 
childbearing-aged women prescribed valproate, and with regard to the lack of assessment 
of each psychiatrist’s valproate prescription dosage. Therefore, senior psychiatrists with 
enough clinical experience may have the opportunity to examine childbearing-age women 
with more refractory bipolar disorder than junior ones. Further studies are needed to 
clarify this.  
With regard to other psychotropics, especially lithium and carbamazepine 
prescriptions, with regard to which theNICE 192 guideline cautions against girls and 
childbearing-age women (20), frequencies of lithium prescriptions were similar to those 
of valproate; approximately 77% of responding psychiatrists answered that they 
frequently or sometimes tended to prescribe it for bipolar women of childbearing age in 
Japan, and carbamazepine was not as frequently prescribed. These findings are consistent 
with our previous study (21). Fetal exposure to lithium in the first trimester is associated 
with increased risk of cardiac malformations (29). According to the NICE guideline, 
unless lithium is recommended for women planning pregnancies who do not clinically 
respond to other antipsychotics or mood stabilizers, but do respond to lithium, it should 
be avoided in the first trimester (20). However, it was clarified that the adverse effects of 
lithium use on the fetus are dose-dependent (30). Therefore, psychiatrists should be more 
careful when continuously prescribing lithium to girls and women of childbearing 
potential. 
We acknowledge that there are several limitations to this study. First, we were 
unable to measure the real-world valproate prescriptions (including the dosage) of the 
responding psychiatrists. Given that some of female patients with bipolar disorder who 
consulted each responding psychiatrist were expected to have various comorbidities, 
intellectual disabilities, and complications, including epilepsy, early menopause, and 
bilateral ovarian ablation, a valproate prescription may be adequate for them with caution. 
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Second, the response rate of 11.8% was low, although 571 psychiatrists responded to this 
questionnaire in Japan. Third, the items with regard to reproductive-related medical 
interviews were relatively scarce in the questionnaire, which may have influenced the 
correlations between the answers and frequencies of valproate prescriptions. 
 
 
Conclusion 
The present study demonstrates that the majority of psychiatrists frequently or 
occasionally tend to prescribe valproate for women of childbearing age in Japan, although 
almost all answered they did not prescribe valproate to pregnant women. Specifically, 
70% of psychiatrists answered that they frequently or sometimes prescribed valproate for 
women aged 18 to 24 years. Considering that fetal exposure to valproate in the first 
trimester must be avoided and that the high rate of pregnancies that are unplanned or 
unintended, psychiatrists, in principle, should not prescribe valproate to girls and women 
of childbearing age with bipolar disorder.  
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